Brief: Aquestive Therapeutics Receives FDA Acceptance Of New Drug Application (NDA) For Libervant
11/09/2023 13:43
Sept 11 (Reuters) - Aquestive Therapeutics Inc AQST.O :
* AQUESTIVE THERAPEUTICS RECEIVES FDA ACCEPTANCE OF NEW DRUG
APPLICATION (NDA) FOR LIBERVANT (DIAZEPAM) BUCCAL FILM IN
PEDIATRIC PATIENTS AND ASSIGNMENT OF PRESCRIPTION DRUG USER FEE
ACT (PDUFA) DATE
* PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET GOAL DATE
SET FOR
APRIL 28, 2024
Source text for Eikon: ID:nGNXc3K4x8
Further company coverage: AQST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Announces FDA Acceptance Of Anaphylm™ NDA Resubmission And PDUFA Goal Date Of March 16, 2027
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Aquestive rises on US licensing deal for seizure drug with Eton Pharma